FDA REMS: A Pain Policy Balancing Act

Myra Christopher

July 19, 2010

The Food and Drug Administration is moving forward on Risk Evaluation and Mitigation Strategies (REMS) for Extended-Release and Long-Acting Opioid Analgesics.

What do those strategies mean for people in chronic pain, and what does it mean for physicians who wish to prescribe such medications?

Myra Christopher, president and CEO of the Center for Practical Bioethics, explains in this edition of The Bioethics Channel with Lorell LaBoube.

Link: Podcast, FDA REMS: A Pain Policy Balancing Act, 14 minutes